The Phase I/IIa trial of HDP-101, an ATAC candidate for the treatment of relapsed or refractory multiple myeloma, is underway, biotech company Heidelberg Pharma has announced. 

The Phase I/IIa trial will evaluate Cohort 9 of HDP-101 after the Safety Review Committee (SRC) confirmed that the 140 µg/kg dose level administered in Cohort 8 was safe and well tolerated. Based on these findings, the study is now progressing into Cohort 9 with an escalated dose of 175 µg/kg, administered in one dosing arm. 

Eight patients were dosed in Cohort 8 and all patients completed the observation period, demonstrating a favourable safety and tolerability profile throughout. There have been encouraging signs from clinical activity, with patients showing biological activity of HDP-101 and one patient showing a very good partial response. 

The observations add to earlier positive outcomes, including one patient from Cohort 5 who is still on treatment and achieved complete remission, with no detectable tumour cells after ongoing HDP-101 monotherapy following multiple prior treatments. Several patients across different cohorts have shown objective responses and promising anti-tumour activity, further supporting the therapeutic potential of HDP-101 in heavily pretreated patients with relapsed or refractory multiple myeloma. 

“Our lead ATAC candidate HDP-101 continues to demonstrate a strong safety and tolerability profile across all treated patients,” said Dr. András Strassz, Chief Medical Officer at Heidelberg Pharma. “The results from Cohort 8 demonstrate encouraging signs of clinical activity of HDP-101, including a very good partial response in one patient. These early efficacy signals are promising as we advance HDP-101 through the ongoing dose escalation study.” 

Heidelberg Pharma’s Phase I/IIa clinical study is a non-randomised, open-label trial actively enrolling patients with relapsed or refractory multiple myeloma or other BCMA-expressing plasma cell disorders. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HDP-101 in this patient population. 

 

Bruno Quinney, Content Team, DDW